Betamethasone 0.05% | Tretinoin 0.05% | Pracasil 30gm (Post Surgical)

Route: Topical application to post-surgical wounds, scars, or procedure sites once fully epithelialized.

• Apply a thin layer to the affected area as directed by the prescriber, typically once or twice daily.
• Gently massage into the scar or post-surgical site; the Pracasil base will absorb and leave a thin silicone film.
• Avoid application to open wounds or actively oozing tissue. Begin use only after the prescriber confirms adequate wound closure.
• Avoid sun exposure on treated areas; tretinoin increases photosensitivity. Apply sunscreen if daytime use is required.

Application frequency and duration are prescriber-determined based on wound type, location, and healing stage:

• Typically applied once to twice daily to fully closed post-surgical sites.
• Duration is individualized; high-potency corticosteroids should generally not be used continuously for more than 2–4 weeks on any single area without reassessment.
• Tretinoin-induced irritation may require dose adjustment (less frequent application initially) until tolerance develops.

• Betamethasone: Binds intracellular glucocorticoid receptors; the receptor-ligand complex enters the nucleus, upregulates anti-inflammatory genes (lipocortin synthesis, which inhibits phospholipase A2), and suppresses NF-κB-mediated pro-inflammatory transcription. Anti-mitotic effects reduce dermal fibroblast proliferation and collagen overproduction, limiting hypertrophic scar formation.
• Tretinoin: Binds nuclear retinoic acid receptors (RAR-α, -β, -γ), forming complexes that activate retinoid hormone response elements; normalizes follicular/epidermal keratinization, increases epidermal cell turnover, promotes procollagen type I and III synthesis, and inhibits matrix metalloproteinases that degrade dermal collagen.

This combination is used in the post-operative management of surgical scars, hypertrophic scars, and procedural sites where controlled inflammation suppression and epidermal remodeling are desired. Betamethasone limits excessive scarring by modulating fibroblast activity; tretinoin promotes organized collagen remodeling and skin renewal; the Pracasil silicone base provides the occlusive, hydrating effect that underpins silicone gel scar therapy.

Prescriber monitoring:

• Assess for skin atrophy, striae, telangiectasias, and HPA axis suppression with prolonged high-potency corticosteroid use, particularly over large areas or under occlusion.
• Monitor for tretinoin irritation (erythema, dryness, peeling); reduce frequency if needed.
• Ensure wound is fully epithelialized before initiating therapy to prevent corticosteroid-induced delayed wound healing.

Contraindications:

• Application to open or actively infected wounds
• Known hypersensitivity to betamethasone, tretinoin, or silicone excipients
• Pregnancy (tretinoin is Pregnancy Category C; topical retinoids should be avoided)

Warnings & Precautions:

• HPA axis suppression: Prolonged use of betamethasone over large areas, particularly under occlusion (Pracasil may enhance absorption), may suppress adrenal function.
• Skin atrophy: High-potency corticosteroids can cause skin thinning, striae, telangiectasias with extended use.
• Photosensitivity: Tretinoin markedly increases UV sensitivity; recommend sun avoidance or SPF 30+ sunscreen on treated areas.
• Delayed wound healing: Corticosteroids may impair wound healing; apply only to fully closed surgical sites.

Drug Interactions:

• CYP3A4 inhibitors (ketoconazole) may increase systemic betamethasone exposure under enhanced absorption conditions.
• Concurrent use of other topical retinoids or irritants will increase tretinoin-associated irritation.

Common Side Effects: Erythema, dryness, and peeling (tretinoin); localized skin thinning or hypopigmentation with extended corticosteroid use; folliculitis; contact dermatitis.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and heat. Pracasil-based preparations should not be frozen. Keep tightly capped when not in use. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

When should I start using this cream after surgery?

Begin only after your prescriber confirms the wound is fully closed and epithelialized—typically at least 2–3 weeks post-procedure, depending on the surgery. Applying this to open wounds may delay healing due to the corticosteroid component.

Why is tretinoin included in a post-surgical formula?

Tretinoin promotes organized collagen remodeling, normalizes epidermal cell turnover, and stimulates procollagen synthesis, helping the healing skin develop a more normal architecture and potentially reducing visible scarring over time.

What is Pracasil and why is it used as the base?

Pracasil-Plus® is a silicone-based compounding base. Silicone gel is a well-documented material for scar management—it hydrates the stratum corneum, reduces transepidermal water loss, and may soften and flatten hypertrophic scars. It also functions as a delivery vehicle for the active ingredients.

Is this product FDA-approved?

This is a 503A compounded preparation prepared by Genesis Compounding for a specific patient per a prescriber's order. It is not an FDA-approved product. The individual active ingredients (betamethasone and tretinoin) are established pharmaceuticals with well-characterized pharmacology.

Should I avoid sun exposure while using this cream?

Yes. Tretinoin significantly increases photosensitivity. Apply sunscreen (SPF 30 or higher) to treated areas exposed to daylight, or use this preparation at night only, as directed by your prescriber.